About the Authors
- Stephane Régnier
-
* E-mail: stephane.regnier@novartis.com
Affiliation Novartis Pharma AG, Basel, Switzerland
- William Malcolm
-
Affiliation Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Surrey, United Kingdom
- Felicity Allen
-
Affiliation Novartis Pharmaceuticals UK Ltd, Frimley Business Park, Frimley, Surrey, United Kingdom
- Jonathan Wright
-
Affiliation Numerus Ltd, Wokingham, United Kingdom
- Vladimir Bezlyak
-
Affiliation Novartis Pharma AG, Basel, Switzerland
Competing Interests
All authors have read the Journal's submission policy and declare the following competing interests: Stephane Regnier and Vladimir Bezlyak are employees of Novartis Pharma AG. William Malcolm and Felicity Allen are employees of Novartis Pharmaceuticals UK Ltd. William Malcolm, Felicity Allen and Vladimir Bezlyak own Novartis shares. Novartis has exclusive rights to ranibizumab outside the United States of America and Novartis Pharma AG. funded this study. Jonathan Wright is an employee of Numerus Ltd. Numerus Ltd was paid to conduct analyses for this manuscript. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: SR WM FA JW. Analyzed the data: SR WM JW VB. Wrote the paper: SR.